President Donald Trump has signed an executive order to significantly lower prescription drug prices in the U.S. by requiring pharmaceutical companies to match the lowest prices available in other countries. This marks a substantial shift in U.S. drug policy, which has traditionally not engaged in price negotiations or controls, leading to inflated costs for American consumers. The executive order highlights that while the U.S. comprises only about five percent of the global population, it generates three-quarters of worldwide pharmaceutical profits, benefitting from lower prices overseas. Trump claims this action will provide fairer pricing and significant healthcare cost reductions for Americans.
President Donald Trump signed an executive order to require pharmaceutical companies to sell drugs in the U.S. at the same lowest price found in any other country.
The U.S. funds about three-quarters of global pharmaceutical profits despite having less than five percent of the worldâs population.
Trump emphasized that this executive order will stop the unfair subsidization of foreign drugs by American consumers, enabling fair access to medications.
The move is aimed at bringing significant reductions in Americans' healthcare costs, a long-elusive outcome in drug pricing policy.
Collection
[
|
...
]